271 related articles for article (PubMed ID: 19168108)
1. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis.
Park JH; Kim DS; Cho YJ; Kim YJ; Jeong SY; Lee SM; Cho SJ; Yun CW; Jo I; Nam JH
Vaccine; 2009 Mar; 27(13):1974-83. PubMed ID: 19168108
[TBL] [Abstract][Full Text] [Related]
2. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
Yue Y; Xu W; Hu L; Jiang Z; Xiong S
Virology; 2009 Apr; 386(2):438-47. PubMed ID: 19233446
[TBL] [Abstract][Full Text] [Related]
3. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
5. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
Fohlman J; Pauksen K; Morein B; Bjare U; Ilbäck NG; Friman G
Scand J Infect Dis Suppl; 1993; 88():103-8. PubMed ID: 8390713
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
[TBL] [Abstract][Full Text] [Related]
7. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
8. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
Xu W; Shen Y; Jiang Z; Wang Y; Chu Y; Xiong S
Vaccine; 2004 Sep; 22(27-28):3603-12. PubMed ID: 15315839
[TBL] [Abstract][Full Text] [Related]
9. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2008 Dec; 7(10):1557-67. PubMed ID: 19053211
[TBL] [Abstract][Full Text] [Related]
10. Attenuated strain of CVB3 with a mutation in the CAR-interacting region protects against both myocarditis and pancreatitis.
Lasrado N; Gangaplara A; Massilamany C; Arumugam R; Shelbourn A; Rasquinha MT; Basavalingappa RH; Delhon G; Xiang SH; Pattnaik AK; Steffen D; Reddy J
Sci Rep; 2021 Jun; 11(1):12432. PubMed ID: 34127684
[TBL] [Abstract][Full Text] [Related]
11. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
13. [C3d enhances immune response to the secreted form of Coxsackie virus B3 VP1 DNA vaccine].
Zhao N; Han XY; Wang XL; Li J; Li W; Xie LX; Li L; Wang YX
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2561-3. PubMed ID: 18067834
[TBL] [Abstract][Full Text] [Related]
14. Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines.
Kim DS; Nam JH
Expert Opin Biol Ther; 2010 Feb; 10(2):179-90. PubMed ID: 20088713
[TBL] [Abstract][Full Text] [Related]
15. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.
Gauntt CJ; Arizpe HM; Higdon AL; Wood HJ; Bowers DF; Rozek MM; Crawley R
J Immunol; 1995 Mar; 154(6):2983-95. PubMed ID: 7533190
[TBL] [Abstract][Full Text] [Related]
16. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.
Dan M; Chantler JK
J Virol; 2005 Jul; 79(14):9285-95. PubMed ID: 15994822
[TBL] [Abstract][Full Text] [Related]
17. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.
Zhang H; Morgan-Capner P; Latif N; Pandolfino YA; Fan W; Dunn MJ; Archard LC
Am J Pathol; 1997 Jun; 150(6):2197-207. PubMed ID: 9176409
[TBL] [Abstract][Full Text] [Related]
18. [A novel DNA vaccine containing endosome-fusogenic peptide prevents CVB3-induced myocarditis in mice].
Xu W; Shen Y; Chen RZ; Xiong SD
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):334-8. PubMed ID: 15059520
[TBL] [Abstract][Full Text] [Related]
19. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis.
Yuan J; Liu Z; Lim T; Zhang H; He J; Walker E; Shier C; Wang Y; Su Y; Sall A; McManus B; Yang D
Circ Res; 2009 Mar; 104(5):628-38. PubMed ID: 19168435
[TBL] [Abstract][Full Text] [Related]
20. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
